Biogen-Idec Wins FDA Approval for MS Drug
- Share via
Biogen-Idec of Cambridge, Mass., won Food and Drug Administration approval for its multiple sclerosis drug Tysabri, formerly called Antegren. Analysts believe the intravenous drug could one day become a $1-billion product.
The drug will be produced in Oceanside, Calif., creating 800 jobs. Biogen-Idec and Elan Corp. of Dublin, Ireland, will co-market it.
The announcement came after stock markets closed. Biogen-Idec closed at $57.43, down 29 cents, on Nasdaq, but rose to $59.60 in after-hours trading.
Denise Gellene
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
